QuidelOrtho Corporation QDEL R2KR3KPHARMA
Company Overview
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.
Why Investors Should Care
Revenue has grown at a 10.4% CAGR over the past five years.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.73B (-1.9% YoY); net profit $-1.13B.
- Trailing 12 Months Year-on-year growth — revenue -10.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 10.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 10.44% |
| 1 Year: | -10.50% |
Stock Price Performance
| 1 Year: | -48.41% |
| 6 Months: | -32.93% |
| 3 Months: | -2.51% |
| 1 Month: | -14.40% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)43.33 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 10.4% over 5 years.
- Generates positive free cash flow.
CONS
- Trading 60.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | QDEL QuidelOrtho Corporation R2KR3KPHARMA | 13.97 | -0.78 | $952.63M | 0.00% | -19.14% | -49.95% | 10.44% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,149.36 | 38.57 | $1.02T | 0.58% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 275.23 | 31.97 | $663.28B | 2.09% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 256.46 | 72.45 | $453.19B | 2.84% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 150.33 | 120.26 | $371.29B | 2.65% | - | 34.70% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 397.14 | 25.54 | $356.47B | 2.33% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 159.99 | 24.20 | $304.10B | 3.03% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 162.70 | 24.36 | $252.33B | 1.98% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | AMGN Amgen Inc. NDXSPXR3KPHARMA | 437.23 | 27.14 | $235.98B | 2.49% | 13.95% | 91.47% | 5.51% | 5.55% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Apr 2021 | Jul 2021 | Oct 2021 | Apr 2022 | Jul 2022 | Oct 2022 | Apr 2023 | Jul 2023 | Oct 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | 176.60M | 509.80M | 1.00B | 613.40M | 783.80M | 846.10M | 665.10M | 744.00M | 711.00M | 637.00M | 727.10M | 692.80M | 613.90M | 699.90M | 619.80M | 630.90M |
| Operating Income | - | 23.30M | 281.80M | 620.70M | 79.70M | 56.80M | 99.60M | -26.90M | 26.30M | -1.76B | -117.50M | 15.00M | 32.60M | -180.70M | -704.80M | -31.80M | -21.80M |
| Net Income | 178.10M | 19.10M | 215.70M | 479.90M | 19.30M | 19.20M | 48.80M | -53.20M | -12.70M | -1.71B | -147.70M | -19.90M | -12.70M | -255.40M | -733.00M | -91.80M | -92.90M |
| Diluted EPS | - | 0.45 | 5.08 | 11.31 | 0.36 | 0.28 | 0.73 | -0.80 | -0.19 | -25.50 | -2.20 | -0.30 | -0.19 | -3.77 | -10.78 | -1.35 | -1.36 |
| R&D Expense | - | 22.60M | 23.70M | 26.40M | 34.20M | 65.60M | 62.30M | 62.40M | 61.50M | 59.20M | 56.30M | 55.90M | 53.20M | 45.70M | 41.50M | 44.90M | 48.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | 1.66B | 1.70B | 3.27B | 3.00B | 2.78B | 2.73B |
| Operating Income | 1.06B | 906.00M | 843.70M | 139.10M | -1.96B | -919.20M |
| Net Income | 810.30M | 704.20M | 548.70M | -10.10M | -2.05B | -1.13B |
| Diluted EPS | 18.60 | 16.43 | 9.56 | -0.15 | -30.54 | -16.69 |
| R&D Expense | 84.30M | 95.70M | 187.90M | 245.00M | 218.70M | 186.20M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 2.43B | 8.86B | 8.56B | 6.42B | 5.77B |
| Total Equity | 559.90M | 1.33B | 1.93B | 4.93B | 5.01B | 2.98B | 1.92B |
| Cash & Equivalents | - | - | 802.80M | 292.90M | 118.90M | 98.30M | 169.80M |
| Long Term Debt | - | - | - | 2.65B | 2.42B | 2.49B | 2.70B |
| Total Liabilities | - | - | 501.00M | 3.92B | 3.56B | 3.44B | 3.85B |
| Current Liabilities | - | - | 323.50M | 1.01B | 833.80M | 998.80M | 966.10M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | 629.70M | 805.90M | 885.30M | 280.20M | 83.00M | 105.20M |
| Investing Cash Flow | -63.30M | -319.50M | -1.64B | -187.60M | -149.90M | -192.70M |
| Financing Cash Flow | -130.30M | -173.10M | 252.00M | -265.80M | 48.80M | 155.80M |
| Capital Expenditure | -64.90M | -292.80M | -140.90M | -209.30M | -195.10M | -188.20M |
| Free Cash Flow | 564.80M | 513.10M | 744.40M | 70.90M | -112.10M | -83.00M |
| Share Buybacks | 43.70M | 103.50M | 74.30M | 7.20M | 0 | 0 |
Ratios (Annual)
Figures in %.
| Metric | Jan 2021 | Jan 2022 | Jan 2023 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | 63.8% | 53.3% | 25.8% | 4.6% | -70.5% | -33.7% |
| Net Margin % | 48.8% | 41.5% | 16.8% | -0.3% | -73.7% | -41.5% |
| ROE % | 60.8% | 36.5% | 11.1% | -0.2% | -68.8% | -58.9% |
| ROCE % | - | 43.0% | 10.7% | 1.8% | -36.1% | -19.1% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Blackrock Inc. | 16.34% | 11.20M | $165.13M |
| 2 | FMR, LLC | 10.74% | 7.36M | $108.54M |
| 3 | Newtyn Management, Llc | 9.66% | 6.62M | $97.65M |
| 4 | Vanguard Portfolio Management LLC | 6.03% | 4.14M | $60.96M |
| 5 | Neuberger Berman Group, LLC | 5.15% | 3.53M | $52.10M |
| 6 | Invesco Ltd. | 5.07% | 3.47M | $51.20M |
| 7 | American Century Companies Inc | 4.82% | 3.31M | $48.75M |
| 8 | Rubric Capital Management LP | 4.82% | 3.31M | $48.73M |
| 9 | Vanguard Capital Management LLC | 4.48% | 3.07M | $45.25M |
| 10 | State Street Corporation | 4.34% | 2.98M | $43.91M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for QDEL
QDEL Stock Eyes Best Day In Over A Year — Point-Of-Care Sale Talks Ignite Rally - Stocktwits
<a href="https://news.google.com/rss/articles/CBMi1gFBVV95cUxPYWEzcXQxcGkyX3dILWtCSDJYTnZ3dE9vVG5rUHhEWVY3YXB3aUl0VTN0LXpmTVBCMW1lSkZBX1FBS1RFb25TbHlTX2VVY0xLVFlQV3MwWjdiSlRpbHZVWTBHZHdnMUZaMzJTQ0czbVhNVXFFSmRvSFBudDFUZHN1MlZYN2cweEMxaHBrZE…
QuidelOrtho Corporation (QDEL) Stock Positioned for Reweighting Towards Peers Amid Deleveraging - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMirwFBVV95cUxNTElpbkd1RXJCU3NjZ3huTk81NE9qRkgyRnlVdGNjVlNQNUlPNUM5b0ozdF9nVG90VnYtSVp2Z2dhRXBSSTRYZUtuRkxRN3dfT0tpZ0xOX1lqa0QweDk1WnJwUGwwNGpTZmlaamphN1VtdnhvSDE1ekwySXByaXJPMUd4VjJPVG9KeFBreW…
QDEL Stock Slumps On Mixed Wall Street Price Target Revisions After Q4 Report - Stocktwits
<a href="https://news.google.com/rss/articles/CBMiwwFBVV95cUxNNDQ3eWE4REgxdk8tRUVwdXRVbVRwdlN2ZllWU1JSSzBFMWpEYXNzMTh5UndtMDFTeVo3VWoyTlY4amt1Z1AxekFuWW5VektzaGJSSTJWSHo3Q1Q5V005UDUwWmx4enZkU2cwV1ZhNXZtcXBxV2plQ1FMOVVLMEpHc2RZRDQ2MmU5T0tFcV…
Why QuidelOrtho (QDEL) Stock Is Nosediving - StockStory
<a href="https://news.google.com/rss/articles/CBMipAFBVV95cUxPMF9LMFZvOHNmT0tZdzVyTUxBQjNtc29LVTBEWmsyVUd5UTBUVUhMQTY3WE5iWWFTalMzQ1lzVlQyNU5sZXpxMmJKeHhPckMtX21OOFdxUnZyWWdaVkI2Wmx2R1hPNU1wWTZlQS0tTGF4Y0w0VWR1RGYxNFlnRlV6U2VRNk92QnctTFZNU2…
$QDEL stock is up 10% today. Here's what we see in our data. - quiverquant.com
<a href="https://news.google.com/rss/articles/CBMioAFBVV95cUxNeG5rZmJfRFRXdm5mR3REZlN3TE1ldzN3UUdoNlZSekZZbllRZ2Zsd00yQmNlbzFWRTRIU1dCWkZoNHRVc18xdWtxQ3NwcXFGa1AxVU5Rb05zNWJQRG01MDdfTFZzZkFJejdBTlhqaGEtVjRqWVNoVG5YdWM5djNHbC1ncXVhTklGLVQ4OX…
QDEL - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE1NOFdMNDFGZEMyN2gxTEhSMkF6dWlrN2JIY1l0NzVKOXRzV2ZZVGFvRzRCN3JJYVpwZzR3U0NneC1CcmM0T0E?oc=5" target="_blank">QDEL</a> <font color="#6f6f6f">Finviz</font>…
QDEL — Frequently Asked Questions
What is the current share price of QuidelOrtho Corporation (QDEL)?
As of 2026-09-07 16:24 PDT, QuidelOrtho Corporation (QDEL) trades at $13.97 on NasdaqGS. Its 52-week range is $9.96 to $35.38.
What is the market capitalisation of QDEL?
QuidelOrtho Corporation (QDEL) has a market capitalisation of $952.63M on NasdaqGS.
What is the P/E ratio of QDEL?
QDEL trades at a trailing price-to-earnings (P/E) ratio of -0.78. The industry average P/E is 25.17. Its price-to-book (P/B) ratio is 0.45.
What is the return on equity (ROE) of QDEL?
QDEL has a return on equity (ROE) of -49.95%. Its return on capital employed (ROCE) is -19.14%.
Is QDEL a good stock to buy?
This page provides a data-driven analysis of QuidelOrtho Corporation (QDEL), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.